Unexplained Recurrent Pregnancy Loss: New Therapeutic Perspectives

N/AActive Not RecruitingNCT06867900

Fondazione Policlinico Universitario Agostino Gemelli IRCCS22 enrolled

Overview

Evaluation of gut permeability and endometrial inflammasome NLRP3 in women with unexplaid recurrent pregnancy loss before-after administration of Bifidobacteriumlongum ES1.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Miscarriage, Recurrent

Interventions

Bifidobacterium Longum ES1DIETARY_SUPPLEMENT

Oral administration of Bifidobacterium Longum ES1 for three months.

Eligibility

Sex: FEMALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Idiopathic recurrent pregnancy loss * Genetic predisposition to celiac disease Exclusion Criteria: \-

Locations (1)

Reasearch Laboratory 3J IRCCS Gemelli

Rome, Italy

Outcomes

Primary Outcomes

Assessment of Endometrial inflammation in RPL women

Analysis of the inflammasome NALP3 expression and activation in serum and endometrial fluid in women with unexplained recurrent pregnancy loss compared to women with uncomplicated pregnancy history.

Time frame: 3 months

Assessment of Gut permeability status in RPL women

Analysis of zonulin expression and activation in serum and endometrial fluid in women with unexplained recurrent pregnancy loss compared to women with uncomplicated pregnancy history.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.